From: Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Number | Percent | |
---|---|---|
Febuxostat | ||
Anti-anemics/antihemorrhagics | 64 | 11.4 |
Darbepoetin alfa | 43 | 7.7 |
Diuretics | 58 | 10.3 |
Furosemide | 25 | 4.4 |
Hydrochlorothiazide | 8 | 1.4 |
Lipid-lowering agents | 39 | 6.9 |
Rosuvastatin | 9 | 1.6 |
Simvastatin | 7 | 1.2 |
Immunosuppressive therapies | 37 | 6.6 |
Tocilizumab | 15 | 2.7 |
Calcium channel blockers | 33 | 5.9 |
Amlodipine | 16 | 2.8 |
Nifedipine | 7 | 1.2 |
Antigout drugs | 31 | 5.5 |
Colchicine | 15 | 2.7 |
Allopurinol | 14 | 2.5 |
NSAIDs | 17 | 3.0 |
Diclofenac | 5 | 0.9 |
Ketoprofen | 3 | 0.5 |
Allopurinol | ||
Diuretics | 247 | 11.3 |
Furosemide | 107 | 4.9 |
Hydrochlorothiazide | 52 | 2.4 |
Spironolactone | 37 | 1.7 |
Antibiotics | 234 | 10.7 |
Amoxicillin | 27 | 1.2 |
Sulfamethoxazole/trimethoprim | 20 | 0.9 |
Immunosuppressive therapies | 163 | 7.5 |
Tocilizumab | 15 | 0.7 |
Cyclosporine | 11 | 0.5 |
Lenalidomide | 11 | 0.5 |
ACEIs | 112 | 5.1 |
Perindopril | 31 | 1.4 |
Ramipril | 26 | 1.2 |
Antigout drugs | 101 | 4.6 |
Colchicine | 75 | 3.4 |
Febuxostat | 14 | 0.6 |
Sartans | 100 | 4.6 |
Valsartan | 28 | 1.3 |
Irbesartan | 19 | 0.9 |
NSAIDs | 87 | 4.0 |
Ibuprofen | 21 | 1.0 |
Diclofenac | 15 | 0.7 |